Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi in a Series A++ financing round. The round was led by ZBJL Capital and Yanrui Asset Management, with participation from existing investor Baidu Venture. The proceeds will be directed towards the iteration of Echo Biotech’s engineering exosomes technology platform and the expansion of its solution offerings.
Company Background and Services
Echo Biotech, in partnership with over 100 key hospitals in China, provides a range of services related to exosomes. These include Contract Manufacturing (CMC), Contract Research (CRO), and Contract Development and Manufacturing Organization (CDMO) services. The company’s offerings are based on its exomics platform, which provides high-throughput multi-omics solutions. Additionally, Echo Biotech focuses on basic research solutions through its engineering exocrine transformation platform, ModiExo, and the research and development of exocrine innovative drugs using its engineering exocrine platform, Echome.
Future Prospects
The Series A++ financing round is a significant step for Echo Biotech, providing the necessary capital to advance its exosomes technology platform. By iterating its technology and expanding its solutions, Echo Biotech aims to enhance its capabilities in the exosomes drug development space. This strategic move positions the company to better serve its partners and contribute to the advancement of exosomes-based therapies, potentially improving patient outcomes in various medical conditions.-Fineline Info & Tech
